Amgen Inc. logo

Amgen Inc. (AMGNCL)

Market Closed
18 Jul, 19:00
293,440. 00
CLP
0
0%
CLP
- Market Cap
19.61 P/E Ratio
9% Div Yield
0 Volume
18.58 Eps
293,440 CLP
Previous Close
Day Range
293,440 293,440
Year Range
261,590 323,490
Want to track AMGNCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 12 days

Summary

AMGNCL closed Friday higher at 293,440 CLP, an increase of 0% from Thursday's close, completing a monthly increase of 0% or 0 CLP. Over the past 12 months, AMGNCL stock gained 11.67%.
AMGNCL pays dividends to its shareholders, with the most recent payment made on Jun 06, 2025. The next estimated payment will be in In 1 month on Sep 06, 2025 for a total of 2.38 CLP.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.24%, based on the last three reports. The next scheduled earnings report is due on Aug 04, 2025.
Amgen Inc. has completed 4 stock splits, with the recent split occurring on Mar 01, 1999.
The company's stock is traded on 14 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

AMGNCL Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Amgen (AMGN) Declines More Than Market: Some Information for Investors

Amgen (AMGN) Declines More Than Market: Some Information for Investors

In the latest trading session, Amgen (AMGN) closed at $294.76, marking a -1.17% move from the previous day.

Zacks | 4 days ago
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More

Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More

This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.

Seekingalpha | 4 days ago
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?

Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 5 days ago

Amgen Inc. Dividends

Amgen Inc. logo
AMGN In 3 weeks
Estimated
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 2 months ago
Paid
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 5 months ago
Paid
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 8 months ago
Paid
Quarterly
$2.25 Per Share
Amgen Inc. logo
AMGN 11 months ago
Paid
Quarterly
$2.25 Per Share
Amgen Inc. logo
AMGN 16 May 2024
Paid
Quarterly
$2.25 Per Share

Amgen Inc. Earnings

5 Aug 2025 (In 1 week) Date
5.22
Cons. EPS
-
EPS
4 Aug 2025 (In 1 week) Date
5.23
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
5.08
Cons. EPS
5.31
EPS
30 Oct 2024 Date
5.11
Cons. EPS
5.58
EPS
Amgen Inc. logo
AMGN In 3 weeks
Estimated
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 2 months ago
Paid
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 5 months ago
Paid
Quarterly
$2.38 Per Share
Amgen Inc. logo
AMGN 8 months ago
Paid
Quarterly
$2.25 Per Share
Amgen Inc. logo
AMGN 11 months ago
Paid
Quarterly
$2.25 Per Share
Amgen Inc. logo
AMGN 16 May 2024
Paid
Quarterly
$2.25 Per Share
5 Aug 2025 (In 1 week) Date
5.22
Cons. EPS
-
EPS
4 Aug 2025 (In 1 week) Date
5.23
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
5.08
Cons. EPS
5.31
EPS
30 Oct 2024 Date
5.11
Cons. EPS
5.58
EPS

Amgen Inc. (AMGNCL) FAQ

What is the stock price today?

The current price is 293,440.00 CLP.

On which exchange is it traded?

Amgen Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is AMGNCL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 9%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 5.23.

When is the next earnings date?

The next earnings report will release on Aug 04, 2025.

Has Amgen Inc. ever had a stock split?

Amgen Inc. had 4 splits and the recent split was on Mar 01, 1999.

Amgen Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Robert A. Bradway CEO
XSGO Exchange
US0311621009 ISIN
US Country
28,000 Employees
16 May 2025 Last Dividend
22 Nov 1999 Last Split
17 Jun 1983 IPO Date

Overview

Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.

Products and Services

  • Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
  • Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
  • Prolia - Addresses osteoporosis in postmenopausal women.
  • XGEVA - Prevents skeletal-related events.
  • Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
  • Nplate - Treats immune thrombocytopenia.
  • KYPROLIS - For relapsed or refractory multiple myeloma patients.
  • Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
  • EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
  • Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
  • BLINCYTO - For patients with acute lymphoblastic leukemia.
  • TEPEZZA - Treats thyroid eye disease.
  • KRYSTEXXA - Addresses chronic refractory gout.
  • Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.

Contact Information

Address: One Amgen Center Drive
Phone: 805 447 1000